Posted by Michael Wonder on 19 Jul 2021
Will CMS find aducanumab reasonable and necessary for Alzheimer disease after FDA approval?
19 July 2021 - The recent US FDA approval of aducanumab for the treatment of Alzheimer disease triggered both praise and criticism from various advocacy groups, but a more important decision regarding the drug—whether to pay for it—will now need to be undertaken by the federal government.
This next decision offers a window into both the challenging politics of value based health care and the difficult administration of pharmaceutical policy in the US.
